Filing Details
- Accession Number:
- 0001415889-24-019169
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-03 16:13:01
- Reporting Period:
- 2024-07-02
- Accepted Time:
- 2024-07-03 16:13:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1623526 | Stoke Therapeutics Inc. | STOK | Pharmaceutical Preparations (2834) | 471144582 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1780085 | M. Huw Nash | C/O Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford MA 01730 | Chief Business Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-07-02 | 2,467 | $13.10 | 33 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-07-02 | 33 | $13.90 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).